The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism
Open accessAbstract
BACKGROUND: The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism is controversial. METHODS: In a randomized, double-blind trial, we compared tenecteplase plus heparin with placebo plus heparin in normotensive patients with intermediate-risk pulmonary embolism. Eligible patients had right ventricular dysfunction on echocardiography or computed tomography, as well as myocardial injury as indicated by a positive test for cardiac troponin I or troponin T. The primary outcome was death or hemodynamic decompensation (or collapse) within 7 days after randomization. The main safety outcomes were major extracranial bleeding and ischemic or hemorrhagic stroke within 7 days after randomization. RESULTS: Of 1006 patients who underwent randomization, 1005 were included in the intention-to-treat analysis. Death or hemodynamic decompensation occurred in 13 of 506 patients (2.6%) in the tenecteplase group as compared with 28 of 499 (5.6%) in the placebo group (odds ratio, 0.44; 95% confidence interval, 0.23 to 0.87; P=0.02). Between randomization and day 7, a total of 6 patients (1.2%) in the tenecteplase group and 9 (1.8%) in the placebo group died (P=0.42). Extracranial bleeding occurred in 32 patients (6.3%) in the tenecteplase group and 6 patients (1.2%) in the placebo group (P<0.001). Stroke occurred in 12 patients (2.4%) in the tenecteplase group and was hemorrhagic in 10 patients; 1 patient (0.2%) in the placebo group had a stroke, which was hemorrhagic (P=0.003). By day 30, a total of 12 patients (2.4%) in the tenecteplase group and 16 patients (3.2%) in the placebo group had died (P=0.42). CONCLUSIONS: In patients with intermediate-risk pulmonary embolism, fibrinolytic therapy prevented hemodynamic decompensation but increased the risk of major hemorrhage and stroke. (Funded by the Programme Hospitalier de Recherche Clinique in France and others; PEITHO EudraCT number, 2006-005328-18; ClinicalTrials.gov number, NCT00639743.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Kucher, N., Boekstegers, P., Müller, O. J., Kupatt, C., Beyer-Westendorf, J., Heitzer, T., Tebbe, U., Horstkotte, J., Müller, R., Blessing, E., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005544 · Cited by 1,151
Self-citation
Cited by
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz405 · Cited by 4,916
Self-citationAntithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Self-citation2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Konstantinides, S. V., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D., Galiè, N., Gibbs, J. S. R., Huisman, M. V., Humbert, M., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu283 · Cited by 3,128
Self-citationOrtel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
“Summary of the evidence We identified 29 systematic reviews(151-179) and 26 RCTs (n 5 2787).(130,180-204) Trials included individuals with an objectively confirmed symptomatic PE.”
BackgroundAntithrombotic Therapy for VTE Disease
Stevens, S. M., Woller, S. C., Kreuziger, L. B., Bounameaux, H., Doerschug, K., Geersing, G.-J., Huisman, M. V., Kearon, C., King, C. S., Knighton, A. J., et al. (2021) · Chest · doi:10.1016/j.chest.2021.07.055 · Cited by 1,043
Metadata
- Authors
- Meyer, G., Vicaut, E., Danays, T., Agnelli, G., Becattini, C., Beyer-Westendorf, J., Bluhmki, E., Bouvaist, H., Brenner, B., Couturaud, F., Dellas, C., Empen, K., Franca, A., Galiè, N., Geibel, A., Goldhaber, S. Z., Jimenez, D., Kozak, M., Kupatt, C., Kucher, N., Lang, I. M., Lankeit, M., Meneveau, N., Pacouret, G., Palazzini, M., Petris, A., Pruszczyk, P., Rugolotto, M., Salvi, A., Schellong, S., Sebbane, M., Sobkowicz, B., Stefanovic, B. S., Thiele, H., Torbicki, A., Verschuren, F., & Konstantinides, S. V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-04-10
- Volume
- 370
- Issue
- 15
- Pages
- 1402-1411
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2159007980
- Cited by
- 1,706
- References
- 2
- FWCI
- 97.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. https://app.cochat.ai/papers/10.1056/nejmoa1302097
- The paper
- Meyer, G., Vicaut, E., Danays, T., Agnelli, G., Becattini, C., Beyer-Westendorf, J., Bluhmki, E., Bouvaist, H., Brenner, B., Couturaud, F., Dellas, C., Empen, K., Franca, A., Galiè, N., Geibel, A., Goldhaber, S. Z., Jimenez, D., Kozak, M., Kupatt, C., . . . Konstantinides, S. V. (2014). Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1302097
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
